Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery

Michelle M. Graham, Daniel I. Sessler, Joel L. Parlow, Bruce M. Biccard, Gordon Guyatt, Kate Leslie, Matthew T.V. Chan, Christian S. Meyhoff, Denis Xavier, Alben Sigamani, Priya A. Kumar, Marko Mrkobrada, Deborah J. Cook, Vikas Tandon, Jesus Alvarez-Garcia, Juan Carlos Villar, Thomas W. Painter, Giovanni Landoni, Edith Fleischmann, Andre LamyRichard Whitlock, Yannick Le Manach, Meylin Aphang-Lam, Juan P. Cata, Peggy Gao, Nicolaas C.S. Terblanche, Pamidimukkala V. Ramana, Kim A. Jamieson, Amal Bessissow, Gabriela R. Mendoza, Silvia Ramirez, Pierre A. Diemunsch, Salim Yusuf, P. J. Devereaux

Research output: Articles / NotesScientific Articlepeer-review

83 Scopus citations


Background: Uncertainty remains about the effects of aspirin in patients with prior percutaneous coronary intervention (PCI) having noncardiac surgery. Objective: To evaluate benefits and harms of perioperative aspirin in patients with prior PCI. Design: Nonprespecified subgroup analysis of a multicenter factorial trial. Computerized Internet randomization was done between 2010 and 2013. Patients, clinicians, data collectors, and outcome adjudicators were blinded to treatment assignment. ( NCT01082874) Setting: 135 centers in 23 countries. Patients: Adults aged 45 years or older who had or were at risk for atherosclerotic disease and were having noncardiac surgery. Exclusions were placement of a bare-metal stent within 6 weeks, placement of a drug-eluting stent within 1 year, or receipt of nonstudy aspirin within 72 hours before surgery. Intervention: Aspirin therapy (overall trial, n = 4998; subgroup, n = 234) or placebo (overall trial, n = 5012; subgroup, n = 236) initiated within 4 hours before surgery and continued throughout the perioperative period. Of the 470 subgroup patients, 99.9% completed follow-up. Measurements: The 30-day primary outcome was death or nonfatal myocardial infarction; bleeding was a secondary outcome. Results: In patients with prior PCI, aspirin reduced the risk for the primary outcome (absolute risk reduction, 5.5% [95% CI, 0.4% to 10.5%]; hazard ratio [HR], 0.50 [CI, 0.26 to 0.95]; P for interaction = 0.036) and for myocardial infarction (absolute risk reduction, 5.9% [CI, 1.0% to 10.8%]; HR, 0.44 [CI, 0.22 to 0.87]; P for interaction = 0.021). The effect on the composite of major and life-Threatening bleeding in patients with prior PCI was uncertain (absolute risk increase, 1.3% [CI, -2.6% to 5.2%]). In the overall population, aspirin increased the risk for major bleeding (absolute risk increase, 0.8% [CI, 0.1% to 1.6%]; HR, 1.22 [CI, 1.01 to 1.48]; P for interaction = 0.50). Limitation: Nonprespecified subgroup analysis with small sample. Conclusion: Perioperative aspirin may be more likely to benefit rather than harm patients with prior PCI. Primary Funding Source: Canadian Institutes of Health Research.

Original languageEnglish
Pages (from-to)237-244
Number of pages8
JournalAnnals of Internal Medicine
Issue number4
StatePublished - 20 Feb 2018
Externally publishedYes


Dive into the research topics of 'Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery'. Together they form a unique fingerprint.

Cite this